欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子抑制剂 > Apoptosis > T-1101 tosylate

浏览历史

S87648

T-1101 tosylate

源叶(MedMol) 98%
  • 英文名:
  • TAI-95 tosylate
  • 别名:
  • CAS号:
  • 2250404-95-4
  • 分子式:
  • C31H31N5O6S3
  • 分子量:
  • 665.80
  • 核磁/质谱:
品牌货号产品规格价格(RMB) 库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
源叶(MedMol) S87648-5mg 98% ¥245.00元 5 - - - EA 加入购物车
源叶(MedMol) S87648-10mg 98% ¥450.00元 3 - - - EA 加入购物车
源叶(MedMol) S87648-25mg 98% ¥850.00元 5 - - - EA 加入购物车
源叶(MedMol) S87648-100mg 98% ¥2150.00元 预计交期:2-3天 - - - EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 产品描述: T-1101 tosylate (TAI-95 tosylate) is a Hec1/Nek2 (Highly expressed in cancer 1 / NIMA-related kinase 2) inhibitor with antitumor activity. T-1101 tosylate is inactive toward normal cells, kinases and hERG
  • 靶点: Hec1/Nek2;Apoptosis; MicrotubuleAssociated
  • 体外研究:
    T-1101 tosylate shows potent in vitro antiproliferative activity (IC50: 14.8-21.5 nM). T-1101 tosylate disrupts the Hec1/Nek2 protein–protein interaction in the cells. T-1101 tosylate (1μM; 3-24 24 hours) decreases the level of Nek2 in a time-dependent manner. T-1101 tosylate (1 µM; 24 hours) induces apoptosis. T-1101 tosylate reduces amounts of cell-cycle related proteins cyclin A1, cyclin B1, and cyclin D1. Apoptosis Analysis Cell Line: HeLa cells Concentration: 1 µM Incubation Time: 24 hours Result: Increased the amount of apoptotic marker proteins cleaved caspase-3 and PARP and decreased the amount of antiapoptotic proteins Mcl-1 and XIAP in HeLa cells. Western Blot Analysis Cell Line: K562 cells Concentration: 1 μM Incubation Time: 3 hours, 6 hours, 16 hours, 24 hours Result: Lowered the level of Nek2 in a time-dependent manner.
  • 体内研究:
    T-1101 tosylate shows good oral bioavailability and thermal stability. Oral co-administration of T-1101 tosylate (2.5 mg/kg; p.o.; twice per day) halves the dose of sorafenib (25 mg/kg to 12.5 mg/kg) required to exhibit comparable in vivo activity towards Huh-7 xenografts. T-1101 tosylate (2.5 mg/kg; p.o.; twice per day) shows significant in vivo activity in mice bearing various human cancer xenografts. Animal Model: SCID mice bearing human Huh-7, BT-474, MCF-7, and MDA-MB-231 xenografts Dosage: 25 mg/kg, 50 mg/kg Administration: Oral administration; twice per day; 28 days Result: Showed significant in vivo activity in mice bearing various human cancer xenografts.
  • 参考文献:
    1. Chuang SH, et al. Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapy. Eur J Med Chem. 2020 Apr 1;191:112118.
  • 溶解性: Soluble  in  DMSO
  • 保存条件: -20℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 1.502 ml 7.51 ml 15.02 ml
    5 mM 0.3 ml 1.502 ml 3.004 ml
    10 mM 0.15 ml 0.751 ml 1.502 ml
    50 mM 0.03 ml 0.15 ml 0.3 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。